AssetMark Inc
SWTX

AssetMark Inc’s SpringWorks Therapeutics SWTX Stock Holding History

AssetMark Inc’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,001
Closed -$188K – 3258
2025
Q2 		$188K Sell
4,001
-48,152
-92% -$2.14M ﹤0.01% 1233
2025
Q1 		$2.3M Buy
52,153
+3,937
+8% +$181K 0.01% 683
2024
Q4 		$1.74M Buy
48,216
+2,196
+5% +$76.7K ﹤0.01% 743
2024
Q3 		$1.47M Buy
46,020
+5,546
+14% +$207K ﹤0.01% 709
2024
Q2 		$1.52M Buy
40,474
+19,693
+95% +$829K ﹤0.01% 676
2024
Q1 		$1.02M Buy
20,781
+4,691
+29% +$217K ﹤0.01% 728
2023
Q4 		$587K Buy
16,090
+5,276
+49% +$138K ﹤0.01% 771
2023
Q3 		$250K Buy
10,814
+1,461
+16% +$40K ﹤0.01% 841
2023
Q2 		$245K Buy
9,353
+3,582
+62% +$94.1K ﹤0.01% 812
2023
Q1 		$149K Buy
5,771
+1,254
+28% +$36.6K ﹤0.01% 863
2022
Q4 		$117K Buy
4,517
+1,210
+37% +$29.8K ﹤0.01% 892
2022
Q3 		$94K Buy
3,307
+1,494
+82% +$42.8K ﹤0.01% 858
2022
Q2 		$45K Buy
1,813
+1,381
+320% +$50.5K ﹤0.01% 942
2022
Q1 		$24K Buy
+432
New +$24.7K ﹤0.01% 1048

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AssetMark Inc's SWTX Position: Q3 2025 in Review

AssetMark Inc sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 4,001 shares — an estimated $188K sold.

AssetMark Inc first reported a position in SWTX in Q1 2022 and held it in 14 quarters. The position peaked at $2.3M in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • AssetMark Inc reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AssetMark Inc sold 4,001 SpringWorks Therapeutics shares in Q3 2025, an estimated $188K.
  • AssetMark Inc first reported a position in SpringWorks Therapeutics in Q1 2022 and held it in 14 quarters.
  • AssetMark Inc's SpringWorks Therapeutics position peaked at $2.3M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on AssetMark Inc's 13F filing for Q3 2025, filed 6 Nov 2025.